@TheBrownHornet My take is that the only weakness in our Ph1 is the small sample size. Ie. The only reason FDA would knock back ODD is likely to be sample size. They could have said this a month ago, rather than go to the trouble of asking for trial results.
Therefore, I believe that ODD is fait accompli.
If the market believes same, then ODD success might already be baked into our SP, or at least somewhat. So any SP rise may not be so large.
As for ODD rejection, yes this would probs send SP back into the teens and would screw us for any upcoming CR initiatives
@TheBrownHornet My take is that the only weakness in our Ph1 is...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.90M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.0¢ | 20.0¢ | $191.1K | 906.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1300 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 9563 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
21.0¢ |
Change
0.000 ( 6.67 %) |
||||
| Open | High | Low | Volume | ||
| 22.0¢ | 22.5¢ | 20.5¢ | 533029 | ||
| Last updated 15.54pm 03/05/2024 ? | |||||
| PAA (ASX) Chart |